Min Min Yang
Chief Executive Officer at PHARMABLOCK SCIENCES (NANJING), INC.
Net worth: 152 M $ as of 2024-06-29
Min Min Yang active positions
| Companies | Position | Start | End |
|---|---|---|---|
| PHARMABLOCK SCIENCES (NANJING), INC. | Chairman | 2014-11-30 | - |
| Chief Executive Officer | 2023-04-20 | - | |
| Founder | 2006-12-25 | - | |
| Director/Board Member | 2014-10-31 | 2014-11-30 | |
| GEMPHARMATECH CO., LTD. | Director/Board Member | 2023-10-18 | - |
Shanghai Ark Biopharmaceutical Co., Ltd.
 Shanghai Ark Biopharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Shanghai Ark Biopharmaceutical Co., Ltd. engages in biopharmaceutical services. It is a biopharmaceutical company which focuses on the discovery and development of novel therapeutics addressing unmet medical needs in respiratory and lung diseases. The firm’s product portfolio covering full disease cycle and patient segmentations, its drug candidates addresses a spectrum of acute and chronic respiratory and lung diseases. The company was founded by Jim Zhen WU and Wu Zheng Bo in April 2014 and is headquartered in Shanghai, China. | Director/Board Member | 2021-02-28 | - |
| Independent Dir/Board Member | 2021-02-28 | - |
Career history of Min Min Yang
Training of Min Min Yang
| Nanjing University | Graduate Degree |
| Auburn University | Doctorate Degree |
Statistics
International
| China | 5 |
| United States | 2 |
Operational
| Director/Board Member | 3 |
| Chief Executive Officer | 1 |
| Chairman | 1 |
Sectoral
| Consumer Services | 3 |
| Health Technology | 3 |
| Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| PHARMABLOCK SCIENCES (NANJING), INC. | Commercial Services |
| GEMPHARMATECH CO., LTD. | Health Technology |
| Private companies | 1 |
|---|---|
Shanghai Ark Biopharmaceutical Co., Ltd.
Shanghai Ark Biopharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Shanghai Ark Biopharmaceutical Co., Ltd. engages in biopharmaceutical services. It is a biopharmaceutical company which focuses on the discovery and development of novel therapeutics addressing unmet medical needs in respiratory and lung diseases. The firm’s product portfolio covering full disease cycle and patient segmentations, its drug candidates addresses a spectrum of acute and chronic respiratory and lung diseases. The company was founded by Jim Zhen WU and Wu Zheng Bo in April 2014 and is headquartered in Shanghai, China. | Health Technology |
- Stock Market
- Insiders
- Min Min Yang
- Experience
